Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma

References

Page 1

	Year	Citations
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Susan D. Demo, Christopher J. Kirk, Monette Aujay, Cancer Research	2007	668
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma David S. Siegel, Thomas G. Martin, Michael Wang, Blood	2012	654
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib Paul G. Richardson, Hannah Briemberg, Sundar Jagannath, Journal of Clinical Oncology	2006	644
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies Owen A. O’Connor, A. Keith Stewart, Marcy K. Vallone, Clinical Cancer Research	2009	298
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma Melissa Alsina, Suzanne Trudel, Richard R. Furman, Clinical Cancer Research	2012	143
Reversible cerebral angiopathy Mathieu Zuber, Emmanuel Touzé, Valérie Domigo, Journal of Neurology Reversible Cerebral AngiopathyMedicineBrain InjuryNeurologyCerebrovascular Intervention	2006	45
Reversible posterior encephalopathy syndrome associated with bortezomib E. Terwiel, R. Hanrahan, Christian J. Lueck, Internal Medicine Journal	2010	27
Bortezomib‐induced reversible posterior leucoencephalopathy syndrome Kevin R. Kelly, Roshni Kalachand, Philip Murphy British Journal of Haematology Degenerative DiseaseBrain InjuryNeurologyNeuropathologyMedicine	2008	26
Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma Marie José Kersten, Raoul P. Kloppenborg, RH van Oers, BMJ Case Reports Hematological MalignancyNeuro-oncologyRelapsed Multiple MyelomaNeurological DisorderMalignant Blood Disorder	2009	13

Page 1